Newsroom

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization...

WASHINGTON--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), empresa líder internacional en salud de la mujer, ha publicado hoy unos datos que revelan que, aunque las pruebas de detección de algunas enfermedades han aumentado entre las mujeres de todo el mundo, sigue existiendo una gran brecha en materia de cribado. Más de la mitad de las mujeres y niñas de 15 años o más, lo que supone aproximadamente 1 500 millones de mujeres, no se sometieron a pruebas de detección de cáncer, hipertensión, diab...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (A...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented in an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, CA from April 17 - 22, 2026. In this now fully enrolled study, STK-012 is being evaluated in combinatio...

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will release its first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company’s website (www.unitedhealthgroup.com). The replay will be available through May 5, 2026, on the website. About UnitedHealth Group UnitedHealth Group (NYSE: UNH) is a health care and well-being c...

WASHINGTON--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), ein weltweit führendes Unternehmen im Bereich der Frauengesundheit, veröffentlichte heute Daten, aus denen hervorgeht, dass zwar die Zahl der Vorsorgeuntersuchungen bei Frauen weltweit gestiegen ist, jedoch nach wie vor eine große Lücke im Zugang zu Vorsorgeuntersuchungen besteht. Über die Hälfte der Frauen und Mädchen ab 15 Jahren – schätzungsweise 1,5 Milliarden Frauen – wurden im vergangenen Jahr nicht auf Krebs, Bluthochdruck, Diabe...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and a...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri...

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ceramic, an AI-native search infrastructure company, today unveiled Supervised Generation at NVIDIA GTC 2026 — a system that augments large language model (LLM) outputs with real-time verification, citations and confidence signals. Supervised Generation is model-agnostic, operating as a trust layer alongside any existing LLM infrastructure, with NVIDIA Nemotron 3 Nano as the featured verification engine. To sign up for our waitlist, visit ceramic.ai, or vis...